Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
The mechanism by which mutations in the presenilin (PS) genes cause the most aggressive form of early-onset Alzheimer's disease (AD) is unknown, but fibroblasts from mutation carriers secrete increased levels of the amyloidogenic A beta 42 peptide, the main component of AD plaques. We established transfected cell and transgenic mouse models that coexpress human PS and amyloid beta-protein precursor (APP) genes and analyzed quantitatively the effects of PS expression on APP processing. In both models, expression of wild-type PS genes did not alter APP levels, alpha- and beta-secretase activity and A beta production. In the transfected cells, PS1 and PS2 mutations caused a highly significant increase in A beta 42 secretion in all mutant clones. Likewise, mutant but not wildtype PS1 transgenic mice showed significant overproduction of A beta 42 in the brain, and this effect was detectable as early as 2-4 months of age. Different PS mutations had differential effects on A beta generation. The extent of A beta 42 increase did not correlate with presenilin expression levels. Our data demonstrate that the presenilin mutations cause a dominant gain of function and may induce AD by enhancing A beta 42 production, thus promoting cerebral beta-amyloidosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous studies have shown that mice coexpressing FAD mutant APP and PS1 transgenes exhibit additive increases in A 𝛃 42 production (Borchelt et al., 1996, 1997; Citron et al., 1997; Holcomb et al., 1998), althoughrarely have more than two A 𝛃 42 -elevating FAD mutations been combined in transgenic animals.”
From Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation (2006) · cites this paper as Citron et al., 1997
In the citing paper
“each of these genetic forms of AD either selectively increases the extracellular concentration of A42 (Suzuki et al., 1994;Borchelt et al., 1996;Duff et al., 1996;Scheuner et al., 1996;Citron et al., 1997) or increases both A42 and A40 (Cai et al., 1993;Citron et al., 1994;Scheuner et al., 1996).”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Citron et al., 1997
In the citing paper
“familial EOAD mutations in PSEN1 and PSEN2 typically result in an increased production of longer and more aggregation-prone derivatives of APP such as Aβ1–42 [47–49].”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [47]
Citations
Cites
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Self-citationScheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Self-citationRogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Self-citationJarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Self-citationIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Self-citationEndoproteolysis of Presenilin 1 and Accumulation of Processed Derivatives In Vivo
Thinakaran, G., Borchelt, D. R., Lee, M. K., Slunt, H. H., Spitzer, L., Kim, G., Ratovitsky, T., Davenport, F., Nordstedt, C., Seeger, M., et al. (1996) · Neuron · doi:10.1016/s0896-6273(00)80291-3 · Cited by 1,013
Self-citationPrusiner, S. B., Scott, M., Foster, D., Pan, K.-M., Groth, D., Mirenda, C., Torchia, M., Yang, S.-L., Serban, D., Carlson, G. A., et al. (1990) · Cell · doi:10.1016/0092-8674(90)90134-z · Cited by 871
Self-citationAmyloid β-Protein and the Genetics of Alzheimer's Disease
Selkoe, D. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.31.18295 · Cited by 799
Self-citationRadzicka, A., & Wolfenden, R. (1988) · Biochemistry · doi:10.1021/bi00405a042 · Cited by 606
Cited by
Items 501–600 of 1,002
Transgenic animals relevant to Alzheimer’s disease
Seabrook, G. R., & Rosahl, T. W. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(98)00170-1 · Cited by 69
Membrane Topology of Alzheimer's Disease-related Presenilin 1
Nakai, T., Yamasaki, A., Sakaguchi, M., Kosaka, K., Mihara, K., Amaya, Y., & Miura, S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.33.23647 · Cited by 68
Auffret, A., Gautheron, V., Repici, M., Kraftsik, R., Mount, H. T. J., Mariani, J., & Rovira, C. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.1856-09.2009 · Cited by 67
Mohajeri, M. H., Saini, K., Schultz, J. G., Wollmer, M. A., Hock, C., & Nitsch, R. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203193200 · Cited by 59
Binding Partners of Alzheimer's Disease Proteins: Are They Physiologically Relevant?
Van Gassen, G., Annaert, W., & Van Broeckhoven, C. (2000) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0306 · Cited by 59
PAR-4 Is Involved in Regulation of β-Secretase Cleavage of the Alzheimer Amyloid Precursor Protein
Xie, J., & Guo, Q. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411933200 · Cited by 60
Oxidative Damage to the c‐fos Gene and Reduction of Its Transcription After Focal Cerebral Ischemia
Cui, J., Holmes, E. H., & Liu, P. K. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0731164.x · Cited by 64
“Damage to nucleic acids may lead to abnormal gene expression and premature neuronal death (Wolozin et al., 1996; Citron et al., 1997; Lamb, 1997; Iadecola et al., 1999).”
BackgroundFamilial Alzheimer Disease Presenilin-1 Mutations Alter the Active Site Conformation of γ-secretase
Chau, D.-M., Crump, C. J., Villa, J. C., Scheinberg, D. A., & Li, Y.-M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.300483 · Cited by 61
Chen, A. C., Kim, S., Shepardson, N., Patel, S., Hong, S., & Selkoe, D. J. (2015) · Journal of Cell Biology · doi:10.1083/jcb.201502001 · Cited by 62
“…whether BACE1, A10, and TACE each occur in distinct complexes with γ-secretase, analogous to how PS1 and PS2 as well as the three principal isoforms of Aph-1 can each form distinct complexes with the other proteins of γ-secretase (De Strooper, 2003; Hébert et al., 2004; Shirotani et al., 2004).”
BackgroundSelf-citationInhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease
Lansbury, P. T. (1997) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(97)80018-x · Cited by 71
Wiley, J. C., Hudson, M. P., Kanning, K. C., Schecterson, L. C., & Bothwell, M. A. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03266.x · Cited by 69
“APP, PS1 and PS2 elevate the production of Ab42, normally a minor Ab peptide species, while having variable effects on production of Ab40 (Suzuki et al. 1994; Borchelt et al. 1996; Duff et al. 1996; Scheuner et al. 1996; Citron et al. 1997; Murayama et al. 1999).”
BackgroundLocalization of presenilin–nicastrin complexes and γ‐secretase activity to the trans‐Golgi network
Siman, R., & Velji, J. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01616.x · Cited by 49
“Of the 29 familial Alzheimer’s disease-linked PS-1 mutations and two PS-2 mutations examined so far, all increase the cellular secretion of the fibrillogenic 42-residue Ab variant (Scheuner et al. 1996; Citron et al. 1997; Murayama et al. 1999).”
BackgroundTesco, G., Kim, T., Diehlmann, A., Beyreuther, K. T., & Tanzi, R. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.51.33909 · Cited by 60
Leutner, S., Czech, C., Schindowski, K., Touchet, N., Eckert, A., & Müller, W. E. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01449-x · Cited by 60
“All mutated sequences were veri®ed by sequence analysis [5].”
MethodMaltese, W. A., Wilson, S., Tan, Y., Suomensaari, S., Sinha, S., Barbour, R., & McConlogue, L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007238200 · Cited by 59
Role of Receptors in Relation to Plaques and Tangles in Alzheimer’s Disease Pathology
Sharma, K., Pradhan, S., Duffy, L. K., Yeasmin, S., Bhattarai, N., & Schulte, M. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312987 · Cited by 60
“Within this range, the Aβ peptides, Aβ40 and Aβ42, are considered the predominant constituent of extracellular insoluble amyloid beta plaques and have neurotoxic properties [43].”
InfluentialCerebrospinal fluid Ab40 and Ab42 natural course and clinical usefulness
Shoji, M. (2002) · Frontiers in Bioscience · doi:10.2741/a826 · Cited by 57
Tandon, A., & Fraser, P. E. (2002) · Genome biology · doi:10.1186/gb-2002-3-11-reviews3014 · Cited by 88
Self-citationCentral and peripheral circadian clocks and their role in Alzheimer's disease
Chauhan, R., Chen, K.-F., Kent, B. A., & Crowther, D. C. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.030627 · Cited by 58
“(Hardy, 1997) (Citron et al., 1997) (Braak and Braak, 1994) PSEN1; PSEN2 Presenilin 1; presenilin 2 PSEN1 and PSEN2 are subunits of the γ-secretase catalytic complex.”
BackgroundSiddappaji, K. K., & Gopal, S. (2021) · AIMS neuroscience · doi:10.3934/neuroscience.2021020 · Cited by 66
“18–50% autosomal dominant early-onset familial AD in 25–65 years age group is most commonly caused by PSEN1 missense mutation suppressing γ-secretase activity with an increased ratio of Aꞵ42 over Aꞵ40 accelerates dementia [101,102].”
BackgroundPhysiological and pathological roles of the γ-secretase complex
Carroll, C. M., & Li, Y.-M. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.04.019 · Cited by 53
Wong, A. H. C., & Josselyn, S. A. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.04.023 · Cited by 60
“The study of presenilin genes greatly advanced our understanding of the cleavage of amyloid precursor protein, which is now known to be an important component of Alzheimer’s disease pathophysiology (34).”
Liu, S., Ando, F., Fujita, Y., Liu, J., Maeda, T., Shen, X., Kikuchi, K., Matsumoto, A., Yokomori, M., Tanabe, C., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006420 · Cited by 59
“Abeta(1-40), and its inhibition enhances brain Abeta deposition.”
BackgroundMethodInfluentialChen, J., Bassot, A., Giuliani, F., & Simmen, T. (2021) · Cells · doi:10.3390/cells10071789 · Cited by 63
“Mutant PS1 and PS2 increase the 42-residue form of β-amyloid [193].”
BackgroundGenetics of Early-Onset Alzheimer Dementia
Rademakers, R., Cruts, M., & Van Broeckhoven, C. (2003) · The Scientific World JOURNAL · doi:10.1100/tsw.2003.39 · Cited by 57
“To establish that the PSEN mutations also alter APP processing, transgenic mice overexpressing wild type and mutant PSEN were constructed[150,151,152].”
MethodWalter, J., Grünberg, J., Schindzielorz, A., & Haass, C. (1998) · Biochemistry · doi:10.1021/bi971763a · Cited by 58
Apoptosis, Neurotrophic Factors and Neurodegeneration
Dragunow, M., MacGibbon, G. A., Lawlor, P. A., Butterworth, N. J., Connor, B. J., Henderson, C. E., Walton, M. R., Woodgate, A.-M., Hughes, P. E., & Faull, R. L. M. (1997) · Reviews in the Neurosciences · doi:10.1515/revneuro.1997.8.3-4.223 · Cited by 64
Molecular Pathogenesis of Alzheimer’s Disease: Reductionist versus Expansionist Approaches
Castellani, R. J., Zhu, X., Lee, H.-G., Smith, M. A., & Perry, G. (2009) · International Journal of Molecular Sciences · doi:10.3390/ijms10031386 · Cited by 54
“The presenilins, initially identified through linkage to early onset familial AD with apparent increased Aβ42 [11-13], are two candidates for the components of the γ-secretase complex [14].”
BackgroundIntracellular Calcium Dysregulation by the Alzheimer’s Disease-Linked Protein Presenilin 2
Galla, L., Redolfi, N., Pozzan, T., Pizzo, P., & Greotti, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030770 · Cited by 63
Subcellular localization of presenilins: association with a unique membrane pool in cultured cells
Kim, S.-H., Lah, J. J., Thinakaran, G., Levey, A., & Sisodia, S. S. (2000) · Neurobiology of Disease · doi:10.1006/nbdi.1999.0280 · Cited by 45
Self-citationSealing one's fate: control of cell death in neurons
Bergeron, L., & Yuan, J. (1998) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(98)80008-1 · Cited by 57
A Unified Hypothesis of Early- and Late-Onset Alzheimer’s Disease Pathogenesis
Atwood, C. S., & Bowen, R. L. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-143210 · Cited by 50
“The overexpression of EOFAD mutant A PP, which promotes A generation [64], has been shown to promote the aberrant re-entry of primary neurons into the cell cycle, as demonstrated by the initial induction of DNA synthesis and cell cycle marker expression, followed by apoptotic cell death [65].”
BackgroundRole of GPCR signaling and calcium dysregulation in Alzheimer's disease
Sushma, & Mondal, A. C. (2019) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2019.103414 · Cited by 61
Metabolic disorder in Alzheimer’s disease
Poddar, M. K., Banerjee, S., Chakraborty, A., & Dutta, D. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00673-z · Cited by 61
Tau is central in the genetic Alzheimer–frontotemporal dementia spectrum
Dermaut, B., Kumar‐Singh, S., Rademakers, R., Theuns, J., Cruts, M., & Broeckhoven, C. V. (2005) · Trends in Genetics · doi:10.1016/j.tig.2005.09.005 · Cited by 60
Du Yan, S., Zhu, Y., Stern, E. D., Hwang, Y. C., Hori, O., Ogawa, S., Frosch, M. P., Connolly, E. S., McTaggert, R., Pinsky, D. J., et al. (2000) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)61485-7 · Cited by 41
In search of an enzyme: the β-secretase of Alzheimer's disease is an aspartic proteinase
Howlett, D. R., Simmons, D. L., Dingwall, C., & Christie, G. (2000) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01647-7 · Cited by 69
Miklossy, J., Taddei, K., Suvà, D., Verdile, G., Fonte, J., Fisher, C., Gnjec, A., Ghika, J. A., Suard, F., Mehta, P. D., et al. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00192-6 · Cited by 62
Presenilin‐1 Exists in Both Pre‐ and Post‐Golgi Compartments and Recycles Via COPI‐Coated Membranes
Réchards, M., Xia, W., Oorschot, V. M. J., Selkoe, D. J., & Klumperman, J. (2003) · Traffic · doi:10.1034/j.1600-0854.2003.t01-1-00114.x · Cited by 55
“FAD-related PS-1 mutations alter the proteolytic processing of the b-amyloid precursor protein (APP), resulting in increased levels of the strongly amyloidogenic 42 amino acid amyloid-b (Ab) form (3,4).”
BackgroundSelf-citationIslam, F., Islam, M. R., Meem, A. F. K., Nafady, M. H., Islam, M. R., Akter, A., Mitra, S., Alhumaydhi, F. A., Emran, T. B., Khusro, A., et al. (2022) · Chemosphere · doi:10.1016/j.chemosphere.2022.136020 · Cited by 56
RetractedKimura, N., Takahashi, M., Tashiro, T., & Terao, K. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.20984 · Cited by 59
“VC 2006 Wiley-Liss, Inc. Key words: Alzheimer’s disease; amyloid b; astrocytes; brain-derived neurotrophic factor; neuritic degeneration Amyloid b peptide (Ab) consists of 40–43 amino acids and is derived from amyloid precursor protein (APP; Citron et al., 1997).”
BackgroundFunctional analyses of major cancer-related signaling pathways in Alzheimer's disease etiology
Guo, J., Cheng, J., North, B. J., & Wei, W. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.07.001 · Cited by 55
Leschik, J., Welzel, A. T., Weissmann, C., Eckert, A., & Brandt, R. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04435.x · Cited by 59
“(2007) 101, 1303–1315 2007 The Authors Ab42 is in agreement with previous data showing that FAD mutations lead to an increased ratio of Ab42 to Ab40, whereas normally Ab42 represents only a minor fraction of the Ab produced (Citron et al. 1997; Eckmann et al. 1997; Araki et al. 2001).”
ResultRedox Labile Site in a Zn4 Cluster of Cu4,Zn4−Metallothionein-3
Roschitzki, B., & Vašák, M. (2003) · Biochemistry · doi:10.1021/bi034816z · Cited by 55
Alzheimer's Disease-like Alterations in Peripheral Cells from Presenilin-1 Transgenic Mice
Eckert, A., Schindowski, K., Leutner, S., Luckhaus, C., Touchet, N., Czech, C., & Müller, W. E. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0378 · Cited by 61
Apolipoprotein E Genotype and Deposits of Aβ40 and Aβ42 in Alzheimer Disease
McNamara, M. J., Gomez-Isla, T., & Hyman, B. T. (1998) · Archives of Neurology · doi:10.1001/archneur.55.7.1001 · Cited by 55
Neurological dysfunctions associated with altered BACE 1‐dependent Neuregulin‐1 signaling
Hu, X., Fan, Q., Hou, H., & Yan, R. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13395 · Cited by 52
“Since BACE1 is critical for Ab generation, inhibition of BACE1 should reduce levels of Ab, particularly the more toxic Ab42, which could benefit AD patients.”
BackgroundInfluentialAβ Measurement by Enzyme-Linked Immunosorbent Assay
Schmidt, S. D., Mazzella, M. J., Nixon, R. A., & Mathews, P. M. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-551-0_34 · Cited by 50
Lalonde, R., Qian, S., & Strazielle, C. (2002) · Behavioural Brain Research · doi:10.1016/s0166-4328(02)00230-9 · Cited by 64
Tau acts as a mediator forAlzheimer's disease‐related synaptic deficits
Liao, D., Miller, E. C., & Teravskis, P. J. (2014) · European Journal of Neuroscience · doi:10.1111/ejn.12504 · Cited by 53
5 Genetic Regulation of Somite Formation
Rawls, A., Wilson‐Rawls, J., & Olson, E. N. (1999) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/s0070-2153(08)60724-3 · Cited by 59
Triggering ferroptosis in neurodegenerative diseases
Nguyen, T. P. M., Alves, F. M., Lane, D. J. R., Bush, A. I., & Ayton, S. (2025) · Trends in Neurosciences · doi:10.1016/j.tins.2025.06.008 · Cited by 64
Khundakar, A. A., & Thomas, A. J. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-148003 · Cited by 54
Zhou, R., Yang, G., & Shi, Y. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1713605114 · Cited by 56
Association of a Presenilin 1 S170F Mutation With a Novel Alzheimer Disease Molecular Phenotype
Piccini, A., Zanusso, G., Borghi, R., Noviello, C., Monaco, S., Russo, R., Damonte, G., Armirotti, A., Gelati, M., Giordano, R., et al. (2007) · Archives of Neurology · doi:10.1001/archneur.64.5.738 · Cited by 53
“A common effect of PSEN1 mutations is the selective increased production of -amyloid (A ) species ending at residue 42 (A 42), the C terminal variant of A peptides that has a stronger tendency to form aggregates.(2,3) To explain this event, it has been proposed that the mutant PSEN1 alters the specificity of the -secr…”
BackgroundMouse Models of Alzheimer's Disease: A Quest for Plaques
Richardson, J. A., & Burns, D. K. (2002) · ILAR Journal · doi:10.1093/ilar.43.2.89 · Cited by 53
Tauists and βaptists United--Well Almost!
Lee, V. M. ‐. (2001) · Science · doi:10.1126/science.1064684 · Cited by 56
Araki, W., Yuasa, K., Takeda, S., Takeda, K., Shirotani, K., Takahashi, K., & Tabira, T. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00638.x · Cited by 56
“The quantitation of Ab in media showed that overexpression of mutant, but not wild-type PS2, resulted in a signi®cant increase in the Ab42/Ab40 ratio, in accordance with previous reports (Tomita et al. 1996; Citron et al. 1997; Shirotani et al. 1999).”
BackgroundResultKawasumi, M., Hashimoto, Y., Chiba, T., Kanekura, K., Yamagishi, Y., Ishizaka, M., Tajima, H., Niikura, T., & Nishimoto, I. (2002) · Neurosignals · doi:10.1159/000067424 · Cited by 54
Therapeutic approaches to Alzheimer’s disease
Thorsett, E. D., & Latimer, L. H. (2000) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(00)00102-2 · Cited by 66
Enhanced generation of intracellular Aβ42 amyloid peptide by mutation of presenilins PS1 and PS2
Takeda, K., Araki, W., & Tabira, T. (2004) · European Journal of Neuroscience · doi:10.1111/j.0953-816x.2003.03135.x · Cited by 53
Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease
D'Onofrio, G., Panza, F., Frisardi, V., Solfrizzi, V., Imbimbo, B. P., Paroni, G., Cascavilla, L., Seripa, D., & Pilotto, A. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.645534 · Cited by 50
“These FAD-linked mutations resulted in increased production of Ab1 -- 42 or an increased Ab1 -- 42/ Ab1 -- 40 ratio in cell-based assays and transgenic mice [48-50].”
BackgroundIwata, H., Tomita, T., Maruyama, K., & Iwatsubo, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007989200 · Cited by 52
Genetic studies in Alzheimer's disease
Tang, Y.-P., & Gershon, E. S. (2003) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2003.5.1/yptang · Cited by 48
“Instead, these missense mutants significantly and specifically enhance γ-secretase cleavage to generate amyloidogenic Aβ42 peptides.(69,89,90,126,127) All these findings point to a central role for PS1 and PS2 in both APP processing and AD pathogenesis.”
BackgroundReversible Pathologic and Cognitive Phenotypes in an Inducible Model of Alzheimer-Amyloidosis
Melnikova, T., Fromholt, S., Kim, H.-S., Lee, D., Xu, G. M., Price, A. R., Moore, B. D., Golde, T. E., Felsenstein, K. M., Savonenko, A. V., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.4251-12.2013 · Cited by 51
“…A peptide through a series of proteolytic events (for review, see Lichtenthaler et al., 2011), generally lead to enhanced levels of A 42 peptides (Citron et al., 1992, 1997; Suzuki et al., 1994; Scheuner et al., 1996; Kwok et al., 2000; De Jonghe et al., 2001; Bentahir et al., 2006; Di et al.,…”
BackgroundBelkacemi, A., & Ramassamy, C. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.11.020 · Cited by 53
Unraveling the complexity of γ-secretase
Wolfe, M. S. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.01.005 · Cited by 55
Searching for new animal models of Alzheimer′s disease
Epis, R., Gardoni, F., Marcello, E. E., Genazzani, A. A., Canonico, P. L., & Luca, M. D. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.10.020 · Cited by 62
Regulation of γ-Secretase Activity in Alzheimer's Disease
Zhou, S., Zhou, H., Walian, P. J., & Jap, B. K. (2007) · Biochemistry · doi:10.1021/bi602509c · Cited by 65
Alzheimer's disease: molecular concepts and therapeutic targets
Fassbender, K. C., Masters, C. L., & Beyreuther, K. T. (2001) · Die Naturwissenschaften · doi:10.1007/s001140100237 · Cited by 61
Animal Models in Biomedical Research
Maurer, K. J., & Quimby, F. W. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-409527-4.00034-1 · Cited by 59
The levels of cerebrospinal fluid Aβ40 and Aβ42(43) are regulated age-dependently
Shoji, M., Kanai, M., Matsubara, E., Tomidokoro, Y., Shizuka, M., Ikeda, Y., Ikeda, M., Harigaya, Y., Okamoto, K., & Hirai, S. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00229-3 · Cited by 50
Cytosolic Proteins Regulate α-Synuclein Dissociation from Presynaptic Membranes
Wislet‐Gendebien, S., D’Souza, C. A., Kawarai, T., George‐Hyslop, P. S., Westaway, D. A., Fraser, P., & Tandon, A. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605965200 · Cited by 56
Self-citationRetractedClosing in on the Amyloid Cascade
Doms, R. W., & Huse, J. T. (2000) · Molecular Neurobiology · doi:10.1385/mn:22:1-3:081 · Cited by 66
Presenilin Affects Arm/β-Catenin Localization and Function in Drosophila
Noll, E., Medina, M., Hartley, D. M., Zhou, J., Perrimon, N., & Kosik, K. S. (2000) · Developmental Biology · doi:10.1006/dbio.2000.9925 · Cited by 59
Czech, C., Lesort, M. J., Tremp, G. L., Terro, F., Blanchard, V., Schombert, B., Carpentier, N., Dreisler, S., Bonici, B., Takashima, A., et al. (1998) · Neuroscience · doi:10.1016/s0306-4522(98)00162-6 · Cited by 51
Substrate recognition and processing by γ-secretase
Wolfe, M. S. (2019) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2019.07.004 · Cited by 53
“Likewise, Phe mutation at position 45 reduced Aβ40 production by preventing trimming of Aβ46 to Aβ43, and Phe mutation at position 44 reduced Aβ42 by blocking its production from Aβ45.”
BackgroundInfluentialFrom proteomics to biomarker discovery in Alzheimer's disease
Ho, L., Sharma, N., Blackman, L., Festa, E. D., Reddy, G., & Pasinetti, G. M. (2005) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.12.025 · Cited by 49
Szapacs, M. E., Numis, A. L., & Andrews, A. M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.04.010 · Cited by 49
(1997) · Biological Chemistry · doi:10.1515/bchm.1997.378.9.937 · Cited by 49
Normal brain development in PS1 hypomorphic mice with markedly reduced γ-secretase cleavage of βAPP
Rozmahel, R. F., Huang, J., Chen, F., Liang, Y., Nguyen, V., Ikeda, M., Lévesque, G., Yu, G., Nishimura, M., Mathews, P. M., et al. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00267-6 · Cited by 51
Self-citationFonte, J., Miklossy, J., Atwood, C., & Martins, R. (2001) · Journal of Alzheimer's Disease · doi:10.3233/jad-2001-3206 · Cited by 49
Hirko, A. C., Meyer, E. M., King, M. A., & Hughes, J. A. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300253 · Cited by 52
Passive Aβ Immunotherapy: Current Achievements and Future Perspectives
Schilling, S., Rahfeld, J.-U., Lues, I., & Lemere, C. A. (2018) · Molecules · doi:10.3390/molecules23051068 · Cited by 45
Ghersi, E., Noviello, C., & D'Adamio, L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405329200 · Cited by 46
Increased susceptibility to amyloid toxicity in familial Alzheimer's fibroblasts
Cecchi, C., Fiorillo, C., Baglioni, S., Pensalfini, A., Bagnoli, S., Nacmias, B., Sorbi, S., Nosi, D., Relini, A., & Liguri, G. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.05.014 · Cited by 48
“Interestingly, all the observed mutations associated with FAD cases lead independently to an increased production of Ab [18,58].”
BackgroundGrilli, M., Diodato, E., Lozza, G., Brusa, R., Casarini, M. J., Uberti, D. L., Rozmahel, R. F., Westaway, D. A., George‐Hyslop, P. S., Memo, M., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.23.12822 · Cited by 52
Self-citationDermaut, B., Theuns, J., Sleegers, K., Hasegawa, H., den Broeck, M. V., Vennekens, K., Corsmit, E., George‐Hyslop, P. S., Cruts, M., van Duijn, C. M., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/340732 · Cited by 48
“Results were compared with PSEN1 L392V, a clinical mutation causing familial EOAD that is known to increase Ab42 levels (Sherrington et al. 1995; Citron et al. 1997), and PSEN1 D385A, an artificial mutation that substantially reduces Ab production (Wolfe et al. 1999).”
ResultChasing genes in Alzheimer?s and Parkinson?s disease
Bertoli‐Avella, A. M., Oostra, B. A., & Heutink, P. (2004) · Human Genetics · doi:10.1007/s00439-004-1097-7 · Cited by 53
Dual Roles of Proteasome in the Metabolism of Presenilin 1
Honda, T., Yasutake, K., Nihonmatsu, N., Mercken, M., Takahashi, H., Murayama, O., Murayama, M., Sato, K., Omori, A., Tsubuki, S., et al. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0720255.x · Cited by 48
ENT1 Regulates Ethanol‐Sensitive EAAT2 Expression and Function in Astrocytes
Wu, J., Lee, M. R., Choi, S. H., Kim, T. H., & Choi, D. (2010) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2010.01187.x · Cited by 49
“ENT1 is sensitive to nM concentrations of nitrobenzylmercaptopurine riboside (NBMPR; also known as nitrobenzylthioionosine, NBTI), whereas ENT2 is resistant to NBMPR even up to mM concentrations (Citron et al., 1997; Coe et al., 1997; Crawford et al., 1998).”
BackgroundSelf-citationStructure, mechanism and inhibition of γ-secretase and presenilin-like proteases
Wolfe, M. S. (2010) · Biological Chemistry · doi:10.1515/bc.2010.086 · Cited by 56
“The diseasecausing missense mutations were found to alter how g-secretase cuts APP, leading to increased proportions of longer, more aggregation-prone forms of Ab (Duff et al., 1996; Lemere et al., 1996; Scheuner et al., 1996; Citron et al., 1997).”
The Metal-binding Properties of DREAM
Craig, T. A., Benson, L. M., Venyaminov, S. Y., Klimtchuk, E. S., Bajzer, Ž., Prendergast, F. G., Naylor, S., & Kumar, R. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109660200 · Cited by 47
Toward the structure of presenilin/γ-secretase and presenilin homologs
Wolfe, M. S. (2013) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2013.04.015 · Cited by 51
Neuroimaging and the Search for a Cure for Alzheimer Disease
Petrella, J. R. (2013) · Radiology · doi:10.1148/radiol.13122503 · Cited by 52
Mouse models of Alzheimer's disease: The long and filamentous road
Phinney, A. L., Horne, P., Yang, J., Janus, C., Bergeron, C., & Westaway, D. (2003) · Neurological Research · doi:10.1179/016164103101202020 · Cited by 46
Self-citationPalacino, J. J., Berechid, B. E., Alexander, P., Eckman, C. B., Younkin, S. G., Nye, J. S., & Wolozin, B. L. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.215 · Cited by 50
Structural Biology of Presenilins and Signal Peptide Peptidases
Tomita, T., & Iwatsubo, T. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.r113.463281 · Cited by 46
Vandersteen, A., Masman, M. F., Baets, G. D., Jonckheere, W., van der Werf, K., Marrink, . J., Rozenski, J., Benilova, I., Strooper, B. D., Subramaniam, V., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.394635 · Cited by 58
“Although quantitative information on the released amounts of the four A isoforms of interest from APP is only available for FAD mutations based on in vitro observations (11, 44, 47, 48), we performed titration assays (Fig.”
MethodDysfunctional γ-Secretase in Familial Alzheimer’s Disease
Wolfe, M. S. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2511-1 · Cited by 51
“Like those FAD mutations in APP near the γ-secretase cleavage site, FAD-mutant PS1 and PS2 lead to increased Aβ42/Aβ40 and overall increased aggregation propensity (Borchelt et al., 1996; Citron et al., 1997; Tomita et al., 1997; Xia et al., 1997).”
Metadata
- Authors
- Citron, M., Westaway, D., Xia, W., Carlson, G., Diehl, T., Levesque, G., Johnson-wood, K., Lee, M., Seubert, P., Davis, A., Kholodenko, D., Motter, R., Sherrington, R., Perry, B., Yao, H., Strome, R., Lieberburg, I., Rommens, J., Kim, S., Schenk, D., Fraser, P., St George Hyslop, P., & Selkoe, D. J.
- Affiliations
- Brigham and Women's Hospital (US)
- University of Toronto (CA)
- McLaughlin Research Institute (US)
- Harvard University (US)
- ORCID
- Venue
- Nature Medicine
- Published
- 1997-01
- Volume
- 3
- Issue
- 1
- Pages
- 67-72
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2081998222
- Cited by
- 1,271
- References
- 28
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 15 · 2023: 20 · 2022: 18 · 2021: 26 · 2020: 29 · 2019: 28 · 2018: 20 · 2017: 20 · 2016: 32 · 2015: 35 · 2014: 38 · 2013: 33 · 2012: 49
- FWCI
- 68.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (64309)
- National Institute on Aging (AG 12749, AG-06173, AG 106812, R01AG012749)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- presenilin mutations, Alzheimer's disease, amyloid-beta 42, presenilin 1, presenilin 2, gain-of-function mutations, transgenic mouse model, beta-amyloidosis, early-onset Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Animals, Brain, Cell Line, Enzyme-Linked Immunosorbent Assay, Genetic Vectors, Hippocampus, Humans, Membrane Proteins, Mice, Transgenic, Mutation, Peptide Fragments, Transfection, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Mice, Presenilin-1, Presenilin-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.